In this context, ADAMs 10 and 17 have been reported as the major proteolytic enzymes involved in HER2 shedding [102], and, of note, higher ADAM10 levels were reported to be significantly correlated with poorer relapse-free survival in a cohort of HER2 positive breast cancer patients [103], suggesting the candidacy of ADAM10 as a potential target to bypass trastuzumab resistance (Table 1). Here, ADAM10 is linked to breast carcinoma.